Increased frequency of the apolipoprotein E2 allele in maintenance haemodialysis patients in Taiwan

Nephrology

Volumn 7, Issue 6, 2002, Pages 277-280

  Hsieh, Ming Chia ^a   Lin, Shiu Ru ^a   Lo, Chao Sheng ^a   Hsin, Shih Chieh ^a   Chen, Hung Chun ^a   Shin, Shyi Jang ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

apo E polymorphism; Diabetic nephropathy; End stage renal disease; Haemodialysis; Taiwan

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ADULT; AGE; AGED; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PRIORITY JOURNAL; TAIWAN;

EID: 0036436971     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1797.2002.00132.x     Document Type: Article

References (30)

1. Siest G, Pillot T, Regis-Bailly A et al. Apolipoprotein E: An important gene and protein to follow in laboratory medicine. Clin. Chem. 1995; 41: 1068-86.
2. Lai YH, Hwang SJ, Yang WC, the Dialysis Surveillance Committee. 1997 National Dialysis Surveillance in Taiwan. Acta Nephrologia Soc. Nephrol. ROC 1997; 11: 177-214.
3. Diamond JR, Karnovsky MJ. Exacerbation of chronic amino-nucleoside nephrosis by dietary cholesterol supplementation. Kidney Int. 1987; 32: 671-7.
4. Kasiske BL, O'Donnell M, Cleary MP, Keane WF. Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int. 1989; 35: 40-8.
5. Mulec H, Johnson S-AA, Bjorck S. Relation between serum cholesterol and diabetic nephropathy. Lancet 1990; 335: 1537-8.
6. Sasaki T, Kurata H, Omura K, Utsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn. J. Med. 1990; 29: 156-63.
7. Shoji T, Nishizawa Y, Toyokawa A, Kawagishi T, Okuno Y, Morii H. Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron 1991; 59: 664-5.
8. Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38: 604-9.
9. Feussner G, Way S, Bommer J, Deppermann D, Griitzmacher P, Ziegler R. Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis. Hum Genet. 1992; 88: 307-12.
10. Oda H, Yorioka N, Ueda C, Nishida Y, Yamakido M. Apolipoprotein E phenotype and renal disease. Contrib. Nephrol. 1997; 120: 22-9.
11. Oda H, Yorioka N, Ueda C, Kushinata S, Yamakido M. Apolipoprotein E polymorphism and renal disease. Kidney Int. 1999; 56 (Suppl. 71): S25-7.
12. Imura T, Kimura H, Gejyo F. Apolipoprotein E phenotypes in hemodialysis patients. Kidney Int. 1999; 56 (Suppl. 71): S245-7.
13. Eto M, Watanabe K, Ishii K. A racial difference in apolipoprotein E allele frequencies between the Japanese and Caucasian populations. Clin. Genet. 1986; 30: 422-7.
14. Yen YC, Liu CK, Lung FW, Chong MY. Apolipoprotein E polymorphism and Alzheimer's disease. Kaohsiung J. Med. Sci. 2001; 17: 190-7.
15. Asakawa J, Takahashi N, Rosenblum BB, Neel JV. Two-dimensional gel studies of genetic variation in the plasma proteins of American-Indians and Japanese. Hum. Genet. 1985; 70: 222-30.
16. Tsuchiya S, Yamamouchi Y, Onuki M et al. Frequencies of apolipoproteins E5 and E7 in apparently healthy Japanese. Jpn. J. Hum. Genet. 1985; 30: 271-8.
17. Hsieh MC, Lin SR, Yang YC, Chen HC, Lin JN, Shin SJ. Higher frequency of apolipoprotein E2 allele in type 2 diabetic patients with nephropathy in Taiwan. J. Nephrol. (in press).
18. US Renal Data System. USRDS Annual Data Report. The National Institute of Health. Bethesda: National Institute of Diabetes and Digestive and Kidney Diseases, 1998.
19. Murabito JM, Evans JC, Larson MG, Levy D. Prognosis after the onset of coronary heart disease: An investigation of differences in outcome between the sexes according to initial coronary disease presentation. Circulation 1993; 88: 2548-55.
20. Wang XL, McCredie RM, Wilcken DEL. Polymorphism of the Apolipoprotein E gene and severity of coronary artery disease defined by angiography. Arteriosclerosis Thrombosis Vasc. Biol. 1995; 15: 1030-4.
21. Keane WF, Mulcahy WS, Kasiske BL, Kim Y, O'Donnell MP. Hyperlipidemia and progressive renal disease. Kidney Int. 1991; 39 (Suppl. 31): S41-8.
22. Nordestgaard BG, Stender S, Kjeldsen K. Severe hypertriglyceridemia, large lipoproteins and protection against atherosclerosis. Scand. J. Clin. Lab. Invest. 1987; 47 (Suppl. 186): S7-12.
23. Oda H, Utsumi C, Nishida Y, Yorioka N, Yamakido M. Role of apolipoprotein Apo E polymorphism in patients with kidney diseases. J. Am. Soc. Nephrol. 1994; 5: 339 (Abstract).
24. Kao JT, Tsai KS, Chang CJ, Huang PC. The effects of apolipoprotein E polymorphism on the distribution of lipids and lipoproteins in the Chinese population. Atherosclerosis 1995; 114: 55-9.
25. Blue ML, Williams DL, Zucker S, Khan SA, Blum CB. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc. Natl Acad. Sci. USA 1983; 80: 283-7.
26. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-30.
27. Camejo G, Hurt-Camejo E, Olsson U, Bondjers G. Proteoglycans and lipoproteins in atherosclerosis. Curr. Opin. Lipidol. 1993; 4: 385-91.
28. Saito T, Sato H, Oikawa S et al. Lipoprotein glomerulopathy: Report of a normolipidemic case and review of the literature (review). Am. J. Nephrol. 1993; 13: 64-8.
29. Mourad G, Djamali A, Turc-Baron C, Cristol JP. Lipoprotein glomerulopathy: A new cause of nephritic syndrome after renal transplantation. Nephrol. Dial. Transplant. 1998; 13: 1292-4.
30. Miyata T, Sugiyama S, Nangaku M et al. Apolipoprotein E2/E5 variants in lipoprotein glomerulopathy recurred in transplanted kidney. J. Am. Soc. Nephrol. 1999; 10: 1590-5.